Abstract
Several vaccine candidates for control of the Coronavirus disease 19 (COVID19) are in phase three trials, with some being approved in different countries. A limited initial supply of vaccine doses is likely in most countries, and will require a judicious vaccination strategy to be developed until supply is unlimited. Vaccines may be effective as post-exposure prophylaxis (PEP) in contacts, but no data are yet available for COVID19 vaccines. If vaccines do have efficacy as PEP, this provides more options for strategies with limited supply. We simulated an epidemic response with limited supply (targeted or ring vaccination) and mass vaccination for the State of New South Wales (NSW) in Australia. For targeted vaccination, the effectiveness of vaccinating young adults was compared to older adults. For mass vaccination, we tested outcomes for varying vaccine efficacy and distribution capacities, and for ring vaccination, we tested different contacts tracing rates. With a limited vaccine stockpile of 1 million doses in NSW, if there is efficacy as PEP, the most efficient way to control COVID19 will be ring vaccination, however at least 90% of contacts per case needs to be traced and vaccinated. Age based strategies make minimal impact on the epidemic due to low coverage rates, but vaccinating older people prevents more deaths. Herd immunity and interruption of community transmission can only be achieved with mass vaccination using a high efficacy vaccine. With a 90% efficacy, herd immunity can be achieved by vaccinating 73% of the population. If the vaccine stockpile is unlimited, distributing at least 60,000 doses per day is required to achieve herd immunity. Slower rates of vaccination will result in the population living with COVID19 longer, and higher cases and deaths.
Competing Interest Statement
CR MacIntyre has been on a COVID-19 vaccine advisory board for Seqirus and has consulted on COVID-19 for Astra Zeneca (Australia). She has been on many vaccine advisory boards for other vaccines (influenza, RSV, pneumococcal, zoster) in the past 5 years for Sanofi, Janssen, Seqirus, Merck and Pfizer.
Funding Statement
The study was not funded by external funds.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A - only published data was used in this mathematical modelling study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are from published studies, available in the reference list.
